# CirCode

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/circode

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.circodebio.cn
- Total disclosed funding: $10M
- Latest round: Series A (Aug 15, 2023)
- Investors on record: 4

## About

Established in 2021 and based in Shanghai, China, CirCode is a biomedical developer that focus on circular RNA drugs. The founder Prof. Zefeng Wang served as the professor of the institute of nutrition and health of the Chinese Academy of Sciences and the director of the laboratory of computational biology of the Chinese Academy of Sciences. The Company first discovered in 2014 that cyclic RNA can be translated to generate proteins with different functions in human cells, pioneering the use of cyclic RNA as a novel mRNA therapy. In August 2023, the company closed a round of series A funding.

The Company utilizes its proprietary cyclic RNA technology platform to develop therapeutic drugs and vaccines. The company has an independently developed patent, which is based on the activity of type II intronic self-scrambling nuclease that can ring any RNA in vitro, and a sequence design platform that can design and optimize the sequence of translation initiation elements and coding regions to achieve efficient translation of ring RNA.

The company business is self-develop circular RNA drugs.

## Funding rounds

- Series A, Aug 15, 2023 — Johnson & Johnson Innovation, Superstring Capital Management
- Angel, Jun 29, 2021, $10M — Kaitai Capital, Apricot Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Angel
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series A